NCT02890329 - Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

October 24, 2022

Study Completion Date

August 19, 2026

Conditions

Previously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia, Myelodysplasia-RelatedRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic Syndrome

Interventions

DRUG

Decitabine

Given IV

BIOLOGICAL

Ipilimumab

Given IV

Trial Locations (11)

22908

University of Virginia Cancer Center, Charlottesville

30342

Northside Hospital, Atlanta

33612

Moffitt Cancer Center, Tampa

44106

Case Western Reserve University, Cleveland

91010

City of Hope Comprehensive Cancer Center, Duarte

92093

UC San Diego Moores Cancer Center, La Jolla

95817

University of California Davis Comprehensive Cancer Center, Sacramento

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH